Upon completion of this activity, the participants should be able to:
-
Manage relapsed/refractory small cell lung cancer (SCLC)
-
Review the mechanisms of action of T-cell engagers
-
Diagnose and manage toxicities associated with bispecific T-cell engagers, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)